In gratitude of the loyal support of our members, the CNS is offering complimentary 2021 Annual Meeting registration to all members! Learn more.

  • The Role of Mixed V1a/V2 Vasopressin Receptor Antagonist (Conivaptan) in Prevention and Treatment of Brain Edema After Middle Cerebral Artery Occlusion in Mice

    Final Number:
    335

    Authors:
    Saeed Ansari MD; Peter Cai BA; Pradeepan Saravanapavan MD; Michael F. Waters MD, PhD; Sylvain Dore PhD; Vishnumurthy Shushrutha Hedna

    Study Design:
    Laboratory Investigation

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2013 Annual Meeting

    Introduction: Middle cerebral artery (MCA) occlusion is the leading cause of ischemic stroke worldwide. “Malignant MCA stroke” (MMS), which denotes a large infarction of the MCA territory with associated cytotoxic edema, has a mortality nearing 80%. Current treatments such as osmo-therapy and hemicraniectomy are designed to reduce post-stroke cytotoxic edema, but have substantial limitations and fail to significantly decrease morbidity and/or mortality. The current study proposes a non-surgical alternative by using a mixed arginine vasopressin receptor antagonist as an efficient modality to prevent and treat MMS by influencing cerebral water homeostasis through modulating BBB permeability. Conivaptan (mixed V1a/V2 vasopressin receptor antagonist), which is currently FDA approved to treat euvolemic hyponatremia, was investigated and showed promising results to reduce cerebral edema on post-ischemic stroke in a murine model.

    Methods: Temporary intraluminal MCA occlusion model (tMCAO) was performed in two experimental groups of male C57BL/6 mice aged between 8 to 12 weeks. Single dose of intraperitoneal (IP) Conivaptan 10mg/kg (1.2ml) premixed with 5% dextrose (5D) was administered in the treatment group (n=6). The control group (n=6) received 1.2ml of 5% dextrose intraperitoneally (single dose). Both treatments were administered at 30 minutes of MCA occlusion. Brain sections were stained with 1% TTC 24 hours after tMCAO to measure brain edema via calculation.

    Results: Brain edema average in Conivaptan group was 0.105±0.066mm3 and in control group was 0.275±0.068mm3. Conivaptan demonstrated statistically significant potential to reduce brain edema 24 hours post tMCAO (p = 0.011).

    Conclusions: Conivaptan significantly reduced cerebral edema in the murine MCA occlusion model. These encouraging results support the effectiveness of Conivaptan in brain edema and neuro-protection in the setting of MMS.

    Patient Care: By proofing the efficacy of Conivaptan in preventing and/or treating brain edema in ischemic stroke murine model, this drug can potentially help treating patients undergoing devastating outcomes regarding malignant MCA stroke.

    Learning Objectives: By the conclusion of this session, participants should be able to: 1) Know about the early measures facing malignant MCA stroke, 2) The role of vasopressin receptor antagonists, specifically Conivaptan, in prevention and treatment of brain edema in ischemic stroke.

    References:

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy